09/04/2026
Researchers at the Blumberg Institute, led by Dr. Ju-Tao Guo, in collaboration with Dr. Yanming Du and Dr. Jinhong Chang, are developing innovative therapies aimed at achieving a functional cure for chronic hepatitis B.
Their work includes BSBI-3-02, a next-generation HBV capsid assembly modulator designed to disrupt the hepatitis B virus lifecycle, as well as a liver-targeting innate immune modulator to strengthen the body's antiviral response.
Learn more in our 2025 annual lab report here:https://blumberginstitute.org/wp-content/uploads/2026/04/Annual-Report-2025.pdf